BNGO Bionano Genomics, Inc. - Common Stock
$1.19
가격 · 8월 19, 2026
기준 재무 정보 8월 10, 2026
52주 범위
$1–$6
4% of range
애널리스트 평점
BUY
8 analysts
목표 주가
$5
+320% upside
P/E (TTM)
-0.3
ROE
-58.8%
순이익률
-92.6%
BNGO 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$1.19
시가총액
$13M
P/E (TTM)
-0.3
EPS (TTM)
$-4.85
매출 (TTM)
$29M
배당 수익률
—
ROE
-58.8%
부채/자본
—
52주 범위
$1 – $6
BNGO 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$29M
2017-12-31
→
2025-12-31
EPS
$-4.85
2021-12-31
→
2025-12-31
잉여현금흐름
—
2018-12-31
→
2020-12-31
마진
-92.6%
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
BNGO
동종업계 중앙값
P/E (TTM)
-0.3
31.3
P/S (TTM)
0.5
0.5
P/B
0.3
1.3
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
BNGO
동종업계 중앙값
Operating Margin (영업이익률)
-117.0%
—
Net Profit Margin (순이익률)
-92.6%
-11.4%
ROA
-35.1%
-27.7%
ROE
-58.8%
-58.6%
ROIC
-75.2%
—
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
BNGO
동종업계 중앙값
Current Ratio (유동비율)
2.0
1.7
Quick Ratio (당좌 비율)
0.4
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
BNGO
동종업계 중앙값
Revenue YoY (매출 YoY)
-7.4%
—
Revenue CAGR 3Y (매출 CAGR 3년)
0.84%
—
Revenue CAGR 5Y (매출 CAGR 5년)
27.4%
—
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
BNGO
동종업계 중앙값
BNGO 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
매수
8 명의 애널리스트
- 적극 매수 2 25.0%
- 매수 5 62.5%
- 보유 1 12.5%
- 매도 0 0.0%
- 적극 매도 0 0.0%
12개월 목표 주가
2 명의 애널리스트 · 2026-08-16
중앙값
$5.00
← 모든 목표가 하회
$1.19
저가
$4.00
고가
$6.00
중앙값 목표
$5.00
+320.2%
평균 목표
$5.00
+320.2%
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
평균 서프라이즈
-0.76%
| 기간 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|
| 2026년 6월 30일 | $-0.64 | $-0.70 | 0.06% |
| 2026년 3월 31일 | $-0.76 | $-0.90 | 0.14% |
| 2025년 12월 31일 | $-0.03 | $-1.43 | 1.4% |
| 2025년 9월 30일 | $-1.59 | $-1.95 | 0.36% |
| 2025년 6월 30일 | $-1.99 | $-2.46 | 0.47% |
| 2025년 3월 31일 | $-1.15 | $-3.08 | 1.9% |
| 2024년 12월 31일 | $-15.83 | $-6.12 | -9.7% |
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| BNGO | $16M | -0.3 | -7.4% | -92.6% | -58.8% | — |
| HBIO | $30M | -0.5 | -8.1% | -65.5% | -384.8% | 57.7% |
| CDT | — | — | — | — | — | — |
| BNBX | $6M | -0.0 | 1.1% | -709.5% | -264.9% | 39.3% |
| TMO | $257.86B | 32.7 | 3.9% | 15.0% | 13.0% | — |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 17
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $31M | $36M | $28M | $18M | $9M | $10M | $12M | $10M | |
| Cost of Revenue | $15M | $30M | $27M | $22M | $14M | $6M | $7M | $9M | $6M | |
| R&D Expense | $11M | $25M | $54M | $49M | $22M | $10M | $9M | $9M | $12M | |
| SG&A Expense | $35M | $52M | $93M | $89M | $58M | $31M | $20M | $14M | $14M | |
| Operating Expenses | $47M | $104M | $225M | $138M | $81M | $41M | $29M | $24M | $27M | |
| Operating Income | $-33M | $-104M | $-215M | $-132M | $-77M | $-39M | $-26M | $-20M | $-23M | |
| Interest Expense | · | · | $5M | $298.0K | $927.0K | $3M | $2M | $1M | $590.9K | |
| Interest Income | $1M | $2M | $3M | $2M | $400.0K | · | · | · | · | |
| Other Non-op | $6M | $-10M | $-20M | $-223.0K | $-59.0K | $-7.0K | $-4M | $2M | $-128.0K | |
| Pretax Income | $-26M | $-112M | $-232M | $-131M | $-78M | $-41M | $-30M | $-18M | $-23M | |
| Income Tax | $67.0K | $33.0K | $62.0K | $2M | $-6M | $29.0K | $21.0K | $15.5K | $18.6K | |
| Net Income | $-26M | $-112M | $-232M | $-133M | $-72M | $-41M | $-30M | $-18M | $-23M | |
| EPS (Basic) | $-4.85 | $-88.13 | $-408.60 | $-4.58 | $-0.26 | · | · | · | · | |
| EPS (Diluted) | $-4.85 | $-88.13 | $-408.60 | $-4.58 | $-0.26 | · | · | · | · | |
| Shares (Basic) | 5,445,000 | 1,271,000 | 569,000 | 28,921,000 | 276,782,000 | · | · | · | · | |
| Shares (Diluted) | 5,445,000 | 1,271,000 | 569,000 | 28,921,000 | 276,782,000 | · | · | · | · | |
| EBITDA | $-24M | $-90M | $-202M | $-122M | $-74M | $-37M | $-25M | $-19M | · |
대차대조표 27
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3M | $9M | $18M | $5M | $25M | $38M | $17M | $17M | $1M | |
| Receivables | $5M | $5M | $9M | $7M | $5M | $3M | $6M | $5M | $3M | |
| Inventory | $8M | $13M | $28M | $30M | $12M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $5M | $3M | $6M | $7M | $4M | $2M | $1M | $919.5K | $1M | |
| Other Current Assets | $2M | $1M | $976.0K | $2M | $1M | $462.0K | $457.1K | $384.1K | $550.1K | |
| Current Assets | $45M | $39M | $140M | $157M | $272M | $47M | $28M | $23M | $7M | |
| PP&E (Net) | $15M | $19M | $23M | $18M | $10M | $5M | $2M | $2M | $3M | |
| PP&E (Gross) | $43M | $46M | $42M | $31M | $19M | $12M | $8M | $7M | $7M | |
| Accum. Depreciation | $28M | $27M | $19M | $13M | $9M | $7M | $6M | $5M | $4M | |
| Goodwill | · | · | $0 | $77M | $56M | $7M | $0 | · | · | |
| Intangibles | $4M | $10M | $34M | $41M | $27M | $1M | $0 | · | · | |
| Other Non-current Assets | $3M | $3M | $7M | $2M | $749.0K | $103.0K | $0 | · | · | |
| Total Assets | $74M | $77M | $214M | $308M | $377M | $60M | $30M | $25M | $10M | |
| Accounts Payable | $6M | $7M | $10M | $13M | $11M | $3M | $3M | $1M | $2M | |
| Accrued Liabilities | $5M | $6M | $8M | $11M | $9M | $6M | $3M | $3M | $4M | |
| Current Liabilities | $23M | $37M | $100M | $36M | $22M | $9M | $26M | $5M | $17M | |
| Capital Leases | $2M | $145.0K | $4M | $6M | $5M | $0 | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | $0 | $44.5K | $808.4K | $567.0K | |
| Total Liabilities | $29M | $41M | $118M | $58M | $40M | $25M | $27M | $15M | $17M | |
| Long-term Debt | · | · | · | · | · | $16M | $20M | $9M | $7M | |
| Total Debt | · | · | · | · | $0 | $16M | $20M | $9M | · | |
| Common Stock | $1.0K | $0 | $0 | $3.0K | $29.0K | $19.0K | $3.4K | $1.0K | $8 | |
| Retained Earnings | $-720M | $-693M | $-581M | $-349M | $-216M | $-144M | $-103M | $-73M | $-54M | |
| AOCI | $17.0K | $27.0K | $23.0K | $-1M | $-539.0K | $0 | · | · | · | |
| Stockholders' Equity | $44M | $35M | $96M | $249M | $337M | $35M | $4M | $10M | $-50M | |
| Liabilities + Equity | $74M | $77M | $214M | $308M | $377M | $60M | $30M | $25M | $10M | |
| Shares Outstanding | 10,740,200 | 1,865,400 | 762,600 | 495,300 | 28,960,000 | 189,953,000 | 34,274,469 | 10,055,072 | 77,257 |
현금 흐름 16
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $10M | $14M | $14M | $10M | $3M | $1M | $1M | $1M | $2M | |
| Stock-based Comp | $5M | $10M | $15M | $22M | $10M | $2M | $1M | $1M | $382.8K | |
| Deferred Tax | $0 | $0 | $0 | $2M | $-6M | $0 | · | · | · | |
| Amort. of Intangibles | $5M | $7M | $7M | $6M | $1M | $100.0K | · | · | · | |
| Restructuring | $0 | · | · | · | · | · | · | · | · | |
| Other Non-cash | $-4M | $19M | $78M | $-26M | $-7M | $-241.6K | $-2M | $-4M | · | |
| Operating Cash Flow | $-16M | $-69M | $-125M | $-125M | $-72M | $-38M | $-30M | $-20M | $-21M | |
| CapEx | · | · | · | · | · | $0 | $61.1K | $331.7K | $1M | |
| Investing Cash Flow | $-13M | $74M | $24M | $83M | $-278M | $-2M | $-61.1K | $-331.7K | $-1M | |
| Stock Issued | $31M | $44M | $58M | $23M | · | · | · | · | · | |
| Net Stock Activity | $31M | $44M | $58M | · | · | · | · | · | · | |
| Financing Cash Flow | $24M | $-14M | $114M | $23M | $336M | $62M | $30M | $36M | $18M | |
| Net Change in Cash | $-5M | $-9M | $13M | $-19M | $-14M | $21M | $788.6K | $16M | $-4M | |
| Taxes Paid | $119.0K | $54.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | · | · | · | · | · | $-38M | $-30M | $-20M | · | |
| Levered FCF | · | · | · | · | · | $-41M | $-32M | $-22M | · |
수익성 7
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -117.0% | -337.9% | -596.0% | -473.7% | -428.8% | -453.4% | -255.4% | -170.1% | · | |
| Net Margin | -92.6% | -364.0% | -643.7% | -476.9% | -402.8% | -483.4% | -294.3% | -154.1% | · | |
| Pretax Margin | -92.3% | -363.9% | -643.6% | -470.2% | -434.6% | -483.1% | -294.1% | -154.0% | · | |
| EBITDA Margin | -83.5% | -292.3% | -558.0% | -439.1% | -410.2% | -436.0% | -244.3% | -159.1% | · | |
| ROA | -35.1% | -77.0% | -89.1% | -38.7% | -33.1% | -90.7% | -108.4% | -105.8% | · | |
| ROE | -58.8% | -265.9% | -216.1% | -49.9% | -21.3% | -165.2% | 1583.7% | -145.8% | · | |
| ROIC | -75.2% | -294.0% | -223.9% | -53.6% | -21.2% | -75.0% | -109.3% | -106.6% | · |
유동성 및 지급능력 5
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.0 | 1.1 | 1.4 | 4.4 | 12.5 | 5.2 | 1.1 | 5.1 | · | |
| Quick Ratio | 0.4 | 0.4 | 0.3 | 0.3 | 1.4 | 4.6 | 0.9 | 4.7 | · | |
| Debt / Equity | · | · | · | · | 0.0 | 0.5 | 5.6 | 0.9 | · | |
| LT Debt / Equity | · | · | · | · | 0.0 | 0.5 | 0.0 | 0.9 | · | |
| Interest Coverage | · | · | -42.0 | -441.9 | -83.2 | -15.3 | -11.3 | -14.8 | · |
효율성 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 0.4 | 0.7 | · | |
| Inventory Turnover | 1.5 | 1.5 | 0.9 | 1.0 | 1.8 | 1.7 | 3.0 | 6.3 | · | |
| Receivables Turnover | 5.7 | 4.4 | 4.4 | 4.7 | 4.7 | 1.9 | 1.9 | 3.1 | · |
성장률 3
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -7.4% | -14.8% | 29.9% | 54.6% | 111.5% | · | · | · | · | |
| Revenue CAGR 3Y | 0.84% | 19.6% | 62.0% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 27.4% | · | · | · | · | · | · | · | · |
가치 평가 (TTM) 14
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $29M | $31M | $36M | $28M | $18M | $9M | $10M | $12M | · | |
| Net Income TTM | $-26M | $-112M | $-232M | $-133M | $-72M | $-41M | $-30M | $-18M | · | |
| Market Cap | $16M | $32M | $5.19B | $260.33B | $519.55B | $351.03B | $25.50B | $31.61B | · | |
| Enterprise Value | · | · | · | · | $519.52B | $351.01B | $25.50B | $31.61B | · | |
| P/E | -0.3 | -0.2 | -0.3 | -191.3 | -6900.0 | · | · | · | · | |
| P/S | 0.6 | 1.1 | 143.7 | 9363.8 | 28894.2 | 41283.4 | 2517.4 | 2634.3 | · | |
| P/B | 0.4 | 0.9 | 54.0 | 1043.8 | 1541.1 | 10006.0 | 7056.5 | 3118.5 | · | |
| P / Tangible Book | 0.4 | 1.3 | 83.4 | 1987.8 | 2044.5 | 13279.6 | · | · | · | |
| P / Cash Flow | -1.0 | -0.5 | -41.4 | -2085.7 | -7223.2 | -9161.9 | -863.5 | -1585.1 | · | |
| P / FCF | · | · | · | · | · | -9161.9 | -861.8 | -1559.2 | · | |
| EV / EBITDA | · | · | · | · | -7044.4 | -9468.4 | -1030.5 | -1655.2 | · | |
| EV / FCF | · | · | · | · | · | -9161.3 | -861.9 | -1558.8 | · | |
| EV / Revenue | · | · | · | · | 28892.8 | 41280.8 | 2517.7 | 2633.6 | · | |
| Earnings Yield | -317.0% | -506.5% | -360.3% | -0.52% | -0.01% | · | · | · | · |
손익계산서 17
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $7M | $8M | $7M | $7M | $6M | $8M | $6M | $8M | $9M | $11M | $9M | $9M | $7M | $8M | $7M | |
| Cost of Revenue | $4M | $3M | $5M | $4M | $3M | $4M | $5M | $15M | $5M | $6M | $8M | $7M | $6M | $5M | $6M | $5M | |
| R&D Expense | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $5M | $7M | $10M | $12M | $14M | $15M | $14M | $14M | $13M | |
| SG&A Expense | $9M | $8M | $9M | $9M | $8M | $9M | $12M | $9M | $12M | $19M | $15M | $25M | $27M | $26M | $25M | $21M | |
| Operating Expenses | $12M | $11M | $12M | $12M | $11M | $11M | $15M | $35M | $20M | $34M | $27M | $116M | $42M | $40M | $39M | $34M | |
| Operating Income | $-7M | $-8M | $-9M | $-9M | $-8M | $-8M | $-12M | $-44M | $-17M | $-31M | $-25M | $-113M | $-39M | $-38M | $-38M | $-32M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $122.0K | · | $71.0K | $74.0K | $76.0K | $74.0K | $73.0K | |
| Interest Income | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $800.0K | $400.0K | |
| Other Non-op | $-344.0K | $-619.0K | $363.0K | $-219.0K | $676.0K | $5M | $-8M | $-697.0K | $363.0K | $-1M | $-20M | $-45.0K | $-330.0K | $117.0K | $-39.0K | $5.0K | |
| Pretax Income | $-7M | $-8M | $-8M | $-8M | $-7M | $-3M | $-20M | $-44M | $-16M | $-31M | $-44M | $-113M | $-39M | $-37M | $-37M | $-32M | |
| Income Tax | $7.0K | $10.0K | $36.0K | $14.0K | $10.0K | $7.0K | $1.0K | $24.0K | $26.0K | $-18.0K | $-36.0K | $39.0K | $33.0K | $26.0K | $2M | $28.0K | |
| Net Income | $-7M | $-8M | $-8M | $-9M | $-7M | $-3M | $-20M | $-44M | $-16M | $-31M | $-44M | $-113M | $-39M | $-37M | $-39M | $-32M | |
| EPS (Basic) | $-0.64 | $-0.76 | $-0.12 | $-1.59 | $-1.99 | $-1.15 | $-7.05 | $-30.92 | $-14.41 | $-35.75 | $-402.91 | $-3.22 | $-1.24 | $-1.23 | $-2.24 | $-1.10 | |
| EPS (Diluted) | $-0.64 | $-0.76 | $-0.12 | $-1.59 | $-1.99 | $-1.15 | $-7.05 | $-30.92 | $-14.41 | $-35.75 | $-402.91 | $-3.22 | $-1.24 | $-1.23 | $-2.24 | $-1.10 | |
| Shares (Basic) | 11,546,000 | 10,979,000 | -6,028,000 | 5,338,000 | 3,441,000 | 2,694,000 | -2,165,000 | 1,431,000 | 1,126,000 | 879,000 | -96,135,000 | 35,001,000 | 31,498,000 | 30,205,000 | -313,217,000 | 28,970,000 | |
| Shares (Diluted) | 11,546,000 | 10,979,000 | -6,028,000 | 5,338,000 | 3,441,000 | 2,694,000 | -2,165,000 | 1,431,000 | 1,126,000 | 879,000 | -96,135,000 | 35,001,000 | 31,498,000 | 30,205,000 | -313,217,000 | 28,970,000 | |
| EBITDA | $-7M | $-6M | · | $-9M | $-8M | $-6M | · | $-44M | $-17M | $-28M | · | $-113M | $-39M | $-35M | · | $-32M |
대차대조표 24
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4M | $3M | $3M | $3M | $4M | $4M | $9M | $9M | $10M | $16M | $18M | $35M | $15M | $4M | $5M | $28M | |
| Receivables | $4M | $4M | $5M | $5M | $3M | $3M | $5M | $5M | $6M | $8M | $9M | $9M | $8M | $7M | $7M | $6M | |
| Inventory | $7M | $8M | $8M | $8M | $10M | $11M | $13M | $16M | $23M | $24M | $28M | $34M | $32M | $33M | $30M | $25M | |
| Prepaid Expense | $5M | $5M | $5M | $5M | $3M | $3M | $3M | $4M | $5M | $5M | $6M | $6M | $5M | $7M | $7M | $7M | |
| Other Current Assets | · | · | $2M | · | · | · | $1M | · | · | · | $976.0K | · | · | · | $2M | · | |
| Current Assets | $25M | $39M | $45M | $49M | $43M | $45M | $39M | $47M | $61M | $86M | $140M | $105M | $123M | $143M | $157M | $218M | |
| PP&E (Net) | $13M | $14M | $15M | $16M | $17M | $18M | $19M | $20M | $25M | $25M | $23M | $21M | $20M | $19M | $18M | $16M | |
| PP&E (Gross) | $42M | $43M | $43M | · | · | · | $46M | · | · | · | $42M | · | · | · | $31M | · | |
| Accum. Depreciation | $29M | $29M | $28M | · | · | · | $27M | · | · | · | $19M | · | · | · | $13M | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $77M | $77M | $77M | $56M | |
| Intangibles | $2M | $3M | $4M | $6M | $7M | $8M | $10M | $11M | $30M | $32M | $34M | $36M | $38M | $39M | $41M | $23M | |
| Other Non-current Assets | $2M | $3M | $3M | $2M | $2M | $2M | $3M | $3M | $6M | $7M | $7M | $10M | $3M | $3M | $2M | $802.0K | |
| Total Assets | $48M | $65M | $74M | $79M | $76M | $78M | $77M | $87M | $129M | $158M | $214M | $182M | $271M | $292M | $308M | $324M | |
| Accounts Payable | $5M | $5M | $6M | $6M | $6M | $7M | $7M | $9M | $9M | $10M | $10M | $15M | $12M | $16M | $13M | $9M | |
| Accrued Liabilities | $3M | $4M | $5M | $5M | $3M | $4M | $6M | $6M | $6M | $11M | $8M | $12M | $8M | $9M | $11M | $12M | |
| Current Liabilities | $10M | $21M | $23M | $23M | $24M | $26M | $37M | $33M | $37M | $59M | $100M | $40M | $33M | $38M | $36M | $34M | |
| Capital Leases | $2M | $3M | $2M | $3M | $3M | $0 | $145.0K | $2M | $2M | $3M | $4M | $4M | $5M | $5M | $6M | $5M | |
| Total Liabilities | $16M | $27M | $29M | $29M | $31M | $30M | $41M | $38M | $49M | $75M | $118M | $63M | $57M | $61M | $58M | $42M | |
| Common Stock | $1.0K | $1.0K | $1.0K | $1.0K | $0 | $0 | $0 | $9.0K | $7.0K | $6.0K | $0 | $3.0K | $3.0K | $31.0K | $3.0K | $30.0K | |
| Retained Earnings | $-735M | $-728M | $-720M | $-712M | $-703M | $-696M | $-693M | $-673M | $-629M | $-613M | $-581M | $-537M | $-425M | $-386M | $-349M | $-310M | |
| AOCI | $14.0K | $12.0K | $17.0K | $6.0K | $-10.0K | $14.0K | $27.0K | $2M | $-3.0K | $-16.0K | $23.0K | $-93.0K | $-310.0K | $-665.0K | $-1M | $-2M | |
| Stockholders' Equity | $32M | $37M | $44M | $50M | $45M | $48M | $35M | $49M | $80M | $83M | $96M | $119M | $215M | $231M | $249M | $282M | |
| Liabilities + Equity | $48M | $65M | $74M | $79M | $76M | $78M | $77M | $87M | $129M | $158M | $214M | $182M | $271M | $292M | $308M | $324M | |
| Shares Outstanding | 11,777,300 | 11,276,500 | 10,740,200 | 9,730,400 | 3,909,400 | 3,101,400 | 1,865,400 | 88,468,000 | 70,776,000 | 57,539,000 | 762,533 | 35,349,000 | 33,240,000 | 306,790,000 | 29,718,000 | 296,900,000 |
현금 흐름 9
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $6M | $3M | $3M | $4M | $4M | $3M | $3M | $3M | $2M | |
| Stock-based Comp | $970.0K | $670.0K | $926.0K | $941.0K | $1M | $2M | $2M | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $5M | $6M | |
| Other Non-cash | · | $-393.0K | · | · | · | $-4M | · | · | · | $-3M | · | · | · | $-2M | · | · | |
| Operating Cash Flow | $-5M | $-6M | $-4M | $-6M | $-3M | $-3M | $-7M | $-13M | $-21M | $-28M | $-30M | $-26M | $-37M | $-32M | $-35M | $-29M | |
| Investing Cash Flow | $14M | $5M | $4M | $-5M | $2M | $-14M | $3M | $-5M | $29M | $48M | $-55M | $33M | $30M | $17M | $12M | $8M | |
| Stock Issued | $620.0K | $705.0K | $2M | $13M | $3M | $13M | $7M | $10M | $12M | $15M | $11M | $13M | $18M | $15M | $0 | $23M | |
| Net Stock Activity | · | $705.0K | · | · | · | $13M | · | · | · | $15M | · | · | · | $15M | · | · | |
| Financing Cash Flow | $-10M | $657.0K | $2M | $10M | $1M | $11M | $4M | $6M | $-2M | $-22M | $68M | $13M | $18M | $15M | $146.0K | $23M | |
| Net Change in Cash | $-681.0K | $403.0K | $1M | $-497.0K | $-63.0K | $-6M | $379.0K | $-13M | $6M | $-2M | $-17M | $20M | $11M | $-987.0K | $-23M | $1M |
수익성 7
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -88.3% | -118.1% | · | -115.9% | -115.9% | -131.1% | · | -722.9% | -219.0% | -354.9% | · | -1215.0% | -453.0% | -510.4% | · | -445.2% | |
| Net Margin | -90.8% | -124.2% | · | -115.4% | -101.8% | -48.0% | · | -728.6% | -208.8% | -358.3% | · | -1208.1% | -449.2% | -500.7% | · | -440.5% | |
| Pretax Margin | -90.8% | -124.0% | · | -115.2% | -101.7% | -47.9% | · | -728.2% | -208.4% | -358.5% | · | -1207.6% | -448.9% | -500.3% | · | -440.1% | |
| EBITDA Margin | -88.3% | -83.5% | · | -115.9% | -115.9% | -93.4% | · | -722.9% | -219.0% | -320.6% | · | -1215.0% | -453.0% | -467.3% | · | -445.2% | |
| ROA | -12.0% | -11.6% | · | -10.2% | -6.7% | -2.6% | · | -32.9% | -8.1% | -14.0% | · | -44.5% | -13.1% | -11.6% | · | -9.3% | |
| ROE | -19.3% | -19.4% | · | -17.2% | -10.9% | -4.7% | · | -52.7% | -11.0% | -20.0% | · | -56.2% | -15.6% | -13.7% | · | -10.2% | |
| ROIC | -22.9% | -21.1% | · | -17.2% | -17.2% | -17.6% | · | -89.9% | -21.2% | -37.6% | · | -95.2% | -18.3% | -16.4% | · | -11.4% |
유동성 및 지급능력 3
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.5 | 1.8 | · | 2.1 | 1.8 | 1.7 | · | 1.4 | 1.6 | 1.5 | · | 2.6 | 3.7 | 3.7 | · | 6.5 | |
| Quick Ratio | 0.8 | 0.4 | · | 0.3 | 0.3 | 0.3 | · | 0.4 | 0.4 | 0.4 | · | 1.1 | 0.7 | 0.3 | · | 1.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -255.1 | · | -1594.5 | -530.2 | -497.9 | · | -440.4 |
효율성 3
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.4 | 0.4 | · | 0.3 | 0.2 | 0.2 | · | 0.6 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | |
| Receivables Turnover | 2.1 | 1.8 | · | 1.5 | 1.4 | 1.1 | · | 0.9 | 1.1 | 1.2 | · | 1.3 | 1.4 | 1.2 | · | 1.6 |
가치 평가 (TTM) 9
| 지표 | 추세 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $29M | $27M | · | $27M | $27M | $29M | · | $32M | $35M | $34M | · | $33M | $30M | $27M | · | $24M | |
| Net Income TTM | $-31M | $-27M | · | $-63M | $-70M | $-95M | · | $-204M | $-199M | $-220M | · | $-220M | $-140M | $-131M | · | $-115M | |
| Market Cap | $13M | $13M | · | $17M | $13M | $9M | · | $2.39B | $2.89B | $3.83B | · | $6.43B | $12.17B | $204.32B | · | $326.00B | |
| P/E | -0.2 | -0.2 | · | -0.0 | -0.1 | -0.0 | · | -0.3 | -0.7 | -1.6 | · | -26.8 | -77.9 | -186.6 | · | -455.6 | |
| P/S | 0.5 | 0.5 | · | 0.6 | 0.5 | 0.3 | · | 74.8 | 83.7 | 112.2 | · | 197.0 | 406.0 | 7566.9 | · | 13447.6 | |
| P/B | 0.4 | 0.4 | · | 0.3 | 0.3 | 0.2 | · | 48.9 | 35.9 | 46.3 | · | 54.0 | 56.6 | 882.7 | · | 1157.1 | |
| P / Tangible Book | 0.4 | 0.4 | · | 0.4 | 0.3 | 0.2 | · | 63.2 | 57.4 | 75.1 | · | 77.2 | 121.8 | 1779.1 | · | 1608.3 | |
| P / Cash Flow | · | -2.3 | · | · | · | -3.1 | · | · | · | -136.2 | · | · | · | -6303.7 | · | · | |
| Earnings Yield | -440.7% | -469.2% | · | -2084.8% | -1477.7% | -2947.3% | · | -312.2% | -133.9% | -62.2% | · | -3.7% | -1.3% | -0.54% | · | -0.22% |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $29M | $31M | $36M | $28M | $18M |
| 영업이익률 % | -117.0% | -337.9% | -596.0% | -473.7% | -428.8% |
| 순이익 | $-26M | $-112M | $-232M | $-133M | $-72M |
| 희석 EPS | $-4.85 | $-88.13 | $-408.60 | $-4.58 | $-0.26 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | — | — | — | — | 0.0 |
| 유동비율 | 2.0 | 1.1 | 1.4 | 4.4 | 12.5 |
| 당좌 비율 | 0.4 | 0.4 | 0.3 | 0.3 | 1.4 |
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.
기관 투자자 (13F) 36개의 제출자 · $661K 전체 · 기준일 2026년 6월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
기관 활동 — Q2 2026 대 이전 분기
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 11 (+1 이전 분기 대비) | 7 (0 이전 분기 대비) | 10 (+2 이전 분기 대비) | 2 (-2 이전 분기 대비) | -179K |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
회사 내부자 26 명의 내부자 · 10 임원 · 11 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Erik R. Holmlin | President and CEO | 2023년 2월 15일 A | 841,615 | 0 | 0 | $0 |
| Gulsen Kama | Chief Financial Officer | 2023년 9월 18일 A | — | 0 | 0 | $0 |
| Christopher P. Stewart | Chief Financial Officer | 2023년 2월 15일 A | 231,373 | 0 | 0 | $0 |
| Michael James Ward | Former Chief Financial Officer | 2019년 3월 1일 A | — | 0 | 0 | $0 |
| Soheil Shams | Chief Informatics Officer | 2022년 2월 15일 A | 5,325,378 | 0 | 0 | $0 |
| Richard Shippy | Chief Business Officer | 2022년 2월 15일 A | — | 0 | 0 | $0 |
| Robert J Priar | Chief Commercial Officer | 2021년 6월 1일 A | — | 0 | 0 | $0 |
| Heather Adams | Chief Administrative Officer | 2020년 2월 18일 A | — | 0 | 0 | $0 |
| Warren Robinson | Chief Commercial Officer | 2019년 3월 1일 A | — | 0 | 0 | $0 |
| Han Cao PHD | Chief Scientific Officer | 2018년 10월 1일 A | 112,936 | 0 | 0 | $0 |
| David L Barker | 이사 | 2026년 5월 14일 A | 13,894 | 0 | 0 | $0 |
| Aleksandar Rajkovic | 이사 | 2022년 6월 9일 A | — | 0 | 0 | $0 |
| Vincent Jung-Fai Wong | 이사 | 2022년 6월 9일 A | — | 0 | 0 | $0 |
| Yvonne Linney | 이사 | 2020년 6월 30일 A | — | 0 | 0 | $0 |
| Hannah Mamuszka | 이사 | 2020년 6월 30일 A | — | 0 | 0 | $0 |
| Albert Luderer | 이사 | 2020년 6월 30일 A | — | 0 | 0 | $0 |
| Kristiina Vuori MD | 이사 | 2020년 6월 30일 A | — | 0 | 0 | $0 |
| Junfeng Wang | 이사 | 2019년 6월 6일 A | 2,906,915 | 0 | 0 | $0 |
| Quan Zhou | 이사 | 2019년 6월 6일 A | 2,906,915 | 0 | 0 | $0 |
| Darren Cai | 이사 | 2019년 6월 6일 A | — | 0 | 0 | $0 |
| Alex Reid Hastie | — | 2026년 8월 3일 A | — | 0 | 0 | $0 |
| Mark Adamchak | — | 2026년 8월 3일 A | 253 | 0 | 0 | $0 |
| Jonathan V. Dixon | — | 2026년 8월 3일 A | 239 | 0 | 0 | $0 |
| Mark Borodkin | — | 2026년 8월 3일 A | 868 | 0 | 0 | $0 |
| Alka Chaubey | — | 2026년 6월 3일 F | 620 | 0 | 0 | $0 |
| Christopher J Twomey | — | 2026년 5월 14일 A | 64,500 | 0 | 0 | $0 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
행동주의자 및 5% 이상 소유자 2 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| Innovatus Life Sciences GP, LP, Innovatus Life Sciences Lending Fund I, LP, Innovatus Capital Partners, LLC, Innovatus Life Sciences Offshore GP, LP, Innovatus Life Sciences Offshore Fund I-A, LP ×3 제출 서류 | 2019년 11월 13일 | — | 최초 제출 | — | SEC |
| LC Fund VI, L.P. (2), LC Parallel Fund VI, L.P. (2), LC Healthcare Fund I, L.P. (2), Rosy Shine Limited (2), Legend Holdings (2), Legend Capital (2), Junfeng Wang (2), Quan Zhou (2), Linan Zhu (2), Hao Chen (2), Nengguang Wang (2) | 2019년 6월 7일 | — | 최초 제출 | 수동적 투자 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF 보유 현황 1 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| VXF · VANGUARD INDEX FUNDS | — | — | 2026년 7월 15일 | 일간 |